Tiziana Life Sciences announced positive results from a PET scan of an Alzheimer’s patient treated with their intranasal foralumab. The scan showed a significant reduction in microglia activation, a key marker of neuroinflammation linked to Alzheimer’s progression. This result stems from a three-month treatment under an expanded access program.
This development is particularly exciting because it targets neuroinflammation, a critical aspect of Alzheimer’s and other neurodegenerative diseases often overlooked by therapies focused solely on amyloid and tau proteins. Addressing neuroinflammation may open new avenues for treating Alzheimer’s, especially for moderate stages where effective therapies are lacking. The potential of foralumab as a standalone or combination therapy offers a glimmer of hope in a field desperately needing new treatment options.
The PET scan data, presented at the 2025 AD/PD Conference in Vienna, revealed a marked decrease in the TSPO PET signal, directly indicating reduced microglia activation. This effect mirrors observations in multiple sclerosis patients treated with intranasal foralumab, suggesting a consistent mechanism of action across neuroinflammatory conditions. Importantly, no adverse side effects were reported during the three-month treatment period.
These findings represent a potential turning point in Alzheimer’s treatment. Further studies are crucial to validate these initial results and explore foralumab’s efficacy in larger patient populations. The positive results with foralumab suggest a promising path toward managing neuroinflammation, potentially leading to improved outcomes for Alzheimer’s patients and shaping the future of neurodegenerative disease treatment.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
